Alphastox just put out a report on our Featured Company: iCo Therapeutics (ICO).

iCo Therapeutics is a Vancouver, BC based biotech company headed by Andrew Rae (CEO) and John Meekison (CFO) – both are seasoned veterans of the Health Care space and present a rare combination of technical expertise and capital markets backgrounds.  Andrew is a former Health Care Analyst and John is a former Health Care investment banker.  The company has three assets. Its lead asset (ICO-007) is currently in the largest Phase II trial of its kind in the US with interim data expected before the end of 2012.  Some of the top eye centers in the US alongside the top clinicians are involved in the trial.

iCo is expecting interim data results to be coming out in early Q1 2013 which will bode as a major catalyst for the stock. Watch for additional catalysts in Q1-Q3.

If you would like a copy of the report, just e-mail: [email protected] and put "iCo Report" in the subject line, and we will e-mail to you within the hour.